(Adnkronos) - The expansion of the use of Glp-1 receptor analogues with an indication for weight management +85.7% in 2025 compared to the previous year and a private expenditure of 172.6 million euros, according to data Osmed Aifa leaves two issues open: what evidence is still missing to orient clinics and health policies, and how [...]
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.